The latest market price and purchasing channels of 2025 Opiccapone

Opicapone is a third-generation catechol-O-methyltransferase (COMT) inhibitor. It is mainly used for the management of the "end-of-dose phenomenon" in patients with Parkinson's disease, which is a stage in which the efficacy of levodopa gradually shortens and symptoms rebound and worsen between doses. As a new generation of long-acting COMT inhibitors, the design advantages of opicapone are that it has a longer half-life, can effectively enhance the duration of the efficacy of levodopa when administered once daily, and is not easy to pass through the blood-brain barrier, reducing central side effects. Therefore, opicapone has gradually become a new choice in the combination drug strategy of Parkinson's disease, and has been approved in many European and American countries for the combined treatment of patients with moderate to advanced Parkinson's disease.

Domestically, Opicapone has not yet been officially approved for marketing by the State Food and Drug Administration, so the drug cannot be purchased in domestic pharmacies, hospitals or the medical insurance system. For patients who really need treatment, the drug can only be obtained through cross-border medical channels, overseas medical service platforms or international pharmacies at this stage. According to the currently disclosed overseas market price, the European original version of Opicapone (trade name: Ongentys) is 50 mg, and the price of a box of 30 tablets is approximately RMB 2,000-3,000, which may fluctuate slightly depending on the country and channel of purchase.

Currently, only the original version of Opicapone is on the market in European and American countries, and no official generic drug has yet been approved. This means that when patients purchase drugs from overseas channels, they will almost always face the price of brand-name drugs. At the same time, they should be particularly vigilant about the potential risks of low-price sources and counterfeit products, and obtain drugs through formal international pharmacy platforms, overseas hospital prescriptions, or the hospital’s international medical referral system to ensure drug safety and treatment effectiveness.

Reference materials:https://www.ongentys.com/